Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed

Renal Failure

Volumn 32, Issue 8, 2010, Pages 1000-1004

  Stavroulopoulos, Aristeidis ^a   Nakopoulou, Lydia ^b   Xydakis, Antonios M ^a   Aresti, Vasiliki ^a   Nikolakopoulou, Aggeliki ^a   Klouvas, Georgios ^a  

^a METROPOLITAN HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Acute kidney injury; Acute tubular necrosis; Antifolate; Non small cell lung cancer; Renal failure

Indexed keywords

BICARBONATE; CARBOPLATIN; CREATININE; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; FOLIC ACID; NITROGEN; PACLITAXEL; PEMETREXED; PREDNISONE; SODIUM; UREA; VANDETANIB; VASOPRESSIN;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; ANAMNESIS; ARTICLE; BICARBONATE BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY FUNCTION; LUNG NON SMALL CELL CANCER; MALE; MONONUCLEAR CELL; MULTIPLE CYCLE TREATMENT; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URINALYSIS; VASOPRESSIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DIABETES INSIPIDUS, NEPHROGENIC; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEPHRITIS, INTERSTITIAL;

EID: 77955936552     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.501930     Document Type: Article

References (15)

1. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Alimta, 2009. Available at: http://www. accessdata. fda.gov/drugsatfda-docs/Label/2009/021462s021lbl.pdf. Accessed October 17, 2009.
2. Michels J, Spano JP, Brocheriou I, et al. Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol. 2009;2:53-56.
3. Castro M. Thymidine rescue: An antidote for pemetrexedrelated toxicity in the setting of acute renal failure. J Clin Oncol. 2003;21:4066-4069.
4. Takimoto CH, Hammond-Thelin LA, Latz JE, et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res. 2007;13:2675-2683.
5. van den Bogaert DP, Pouw EM, van Wijhe G, et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2006;1:25-30.
6. Llombart-Cussac A, Martin M, Harbeck N, et al. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res. 2007;13:3652-3659.
7. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26:1698-1704.
8. Vootukuru V, Liew YP, Nally JV. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol. 2006; 23:419-422.
9. Moses AM, Scheinman SJ, Oppenheim A. Marked hypotonic polyuria resulting from nephrogenic diabetes insipidus with partial sensitivity to vasopressin. J Clin Endocrinol Metab. 1984;59:1044-1049.
10. Garofeanu CG, Weir M, Rosas-Arellano MP, et al. Causes of reversible nephrogenic diabetes insipidus: A systematic review. Am J Kidney Dis. 2005;45:626-637.
11. Fernández-Espartero MC, Rodríguez M, de la Mata J. Methotrexate-induced nephrogenic diabetes insipidus: First case report. Rheumatology (Oxford). 2002;41:233-234.
12. Mita AC, Sweeney CJ, Baker SD, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006;24:552-562.
13. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: Biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 2007;6:404-417.
14. Collins JF. Novel insights into intestinal and renal folate transport. Focus on 'Apical membrane targeting and trafficking of the human proton-coupled folate transporter in polarized epithelia.' Am J Physiol Cell Physiol. 2008;294: C381-C382.
15. Damaraju VL, Hamilton KF, Seth-Smith ML, et al. Characterization of binding of folates and antifolates to brush-border membrane vesicles isolated from human kidney. Mol Pharmacol. 2005;67:453-459.